Exclusive License Agreement (EXoZymes) (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
May 12, 2025 |
Jun. 30, 2022 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Common Stock [Member] | ||||
| ExclusiveLicenseAgreementLineItems [Line Items] | ||||
| Issuance of common shares, shares | 19,440 | 1,987,666 | ||
| License Agreement [Member] | ||||
| ExclusiveLicenseAgreementLineItems [Line Items] | ||||
| Payments for patent fees | $ 400,211 | |||
| License fees | $ 7,012 | $ 3,389 | ||
| License Agreement [Member] | Common Stock [Member] | ||||
| ExclusiveLicenseAgreementLineItems [Line Items] | ||||
| Issuance of common shares, shares | 249,689 | |||
| Proceeds from sale of equity securities | $ 5,000,000 | $ 5,000,000 | ||
| Licensed Product [Member] | License Agreement [Member] | ||||
| ExclusiveLicenseAgreementLineItems [Line Items] | ||||
| Payment for licensed product | 250,000 | |||
| Cumulative net sales | 1,000,000 | |||
| Second Licensed Product [Member] | License Agreement [Member] | ||||
| ExclusiveLicenseAgreementLineItems [Line Items] | ||||
| Payment for licensed product | 350,000 | |||
| Cumulative net sales | $ 2,000,000 | |||